Comparative Genomic Hybridization (CGH) Detects Common and Distinct Aberrations in Non-Small Cell Lung Tumors of Different Histology
Posted on: Wednesday, 15 September 2004, 06:00 CDT
113
Aims: Molecular genetic and cytogenetic studies have revealed recurrent genomic aberrations in lung tumors. We performed CGH analysis on a series of non-small cell lung tumors of different histology to identify common and distinct genomic imbalances.
Methods: Surgical tissue samples were collected at the Faculty of Medicine of Uludag University. Genomic tumor DNA was isolated from fresh frozen tissue samples of 21 squamous cell carcinomas, 11 non- squamous cell lung carcinomas (6 adenocarcinomas, 4 large cell carcinomas, 1 adenosquamous carcinoma), and 1 atypical carcinoid. Tumor and normal reference genomic DNA were labeled by nick translation and hybridized to normal metaphase spreads. Fluorescense signal ratios from tumor and reference DNA were analyzed on a Vysis Quips Genetics Workstation.
Results: 17/21 squamous cell carcinomas, 9/11 non-squamous cell carcinomas and the atypical carcinoid revealed chromosomal imbalances. Overrepresentations were more frequent than losses (mean 2.9 vs. 1.5). Overrepresentations at distal 3q were more commonly found in squamous cell carcinomas than in non-squamous cell carcinomas (11/21 vs. 2/11). Similar trends were found for Overrepresentations at 18p (6/21 vs. 0/11) and 22q (5/21 vs. 0/11). Overrepresentations at 5p were detected in 3/21 squamous cell carcinomas and in 6/11 non-squamous cell carcinomas including all 4 large cell carcinomas.
Conclusions: The present data suggest common and distinct genetic pathways in non-small cell lung tumors of different histology. The observed imbalances may help to substantiate the events involved in the tumorigenesis of non-small cell lung tumors.
T. YAKUT1, H.-J. SCHULTEN, B. GUNAWAN, J. WOLF-SALGO, C. ENDERS, L. FZESI
Institut fr Pathologie, Universitt Gttingen
1 Faculty of Medicine, Uludag University, Bursa, Turkey
Copyright Urban & Fischer Verlag 2004
Related Articles
- Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
- AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients With Metastatic Renal Cell Carcinoma
- Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
- Curis Provides Update on Basal Cell Carcinoma Phase I Clinical Trial; Parties Determine to Halt Phase I Trial
- Keryx Biopharmaceuticals, Inc. Announces Positive Data of KRX-0401 (Perifosine) in Patients With Advanced Renal Cell Carcinoma
- Curis Provides Update on Ongoing Basal Cell Carcinoma Phase I Clinical Trial
- Major Dietary Patterns and Risk of Renal Cell Carcinoma in a Prospective Cohort of Swedish Women1
- New Approaches to Medical Treatment of Basal Cell Carcinoma
- Recurrent Squamous Cell Carcinoma in the Neopharynx Treated Successfully With Topical 5-Fluorouracil
- Solitary Cardiac Metastasis From a Clear Cell Carcinoma of the Kidney. A Case Report and Review of the Literature
 |
 |
User Comments (0)
RSS Feeds